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LETTERS TO THE EDITOR
Phosphate intake and the
CARE study
To the Editor: We read with great interest the Calcium
Acetate Renagel Evaluation (CARE) study report [1].
Although this trial was designed according to the best
standards, patients’ weights were unexpectedly greater
than 11% in the sevelamer group. Phosphate metabolism
not only depends on dialytic clearance, but also on in-
take and absorption [2]. Thus, protein (based on 1.2 g
protein/kg/day), and consequently phosphate (a nearly
constant 1.3% of protein) intakes may have been greater
in the sevelamer group by 10 g protein (e.g., 130 mg phos-
phate per day). It would be of great interest to provide
normalized protein nitrogen appearance (nPNA) in or-
der to rule out this confounding factor.
Similar to phosphate intake, we are left without indi-
cation upon vitamin D doses between groups. Indeed,
combination of higher phosphate intake and vitamin D
might have resulted in a larger phosphate absorption, and
impacted on serum phosphate curve over time (Fig. 1A).
Finally, the short duration of the trial might not have al-
lowed for metabolic equilibrium to occur because, in the
calcium acetate group, serum calcium seems to rise as
soon as four weeks after the start (Fig. 2A), consequently
followed by a rise in CaP product at week six, which could
have counterbalanced the slower control of CaP product
by sevelamer over time.
Hyperphosphatemia is present in more than 50% of
maintenance dialysis patients, and there is a great vari-
ability in its care [3]. There is no need to underline the
difficulty to conduct well-designed studies in this field,
but our remark points out some limitations of the strong
conclusions made by Qunibi et al.
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We thank Dr. Fouque for his thoughtful comments
regarding the CARE study [1]. Indeed, baseline demo-
graphics showed a statistically significant difference in
weight between the two treatment groups, such that the
mean weight was 11% greater in the sevelamer-treated
patients. However, analysis by repeated measures logis-
tic regression showed that the difference in weight be-
tween the two groups had no effect on the primary “goal-
attained” outcomes for serum phosphorus or calcium-
phosphorus product. Moreover, three-day dietary histo-
ries were obtained on all patients at baseline, week four,
and week eight to assess dietary intake of calcium and
phosphorus, and there was not a statistically significant
difference between the two groups at any time point dur-
ing the study. Thus, we conclude that the difference in
baseline weight between the two groups does not ac-
count for our finding that calcium acetate-treatment re-
sulted in better control of serum phosphorus and calcium-
phosphorus product than treatment with sevelamer hy-
drochloride. Unfortunately, we do not have data on nor-
malized protein catabolic rate (nPCR) in our CARE
study patients.
Prestudy use of injectable vitamin D preparations was
similar in the two groups; 65% of the calcium acetate
group versus 60% of the sevelamer group was treated
with vitamin D (P = 0.64). The study was designed such
that the patient’s prestudy dose of vitamin D was contin-
ued and maintained constant throughout the eight-week
treatment period. Vitamin D doses were not modified
in response to hypercalcemia or parathyroid hormone
(PTH) levels.
Finally, the time-averaged serum calcium concentra-
tion was higher by 0.63 mg/dL in the calcium acetate
group, whereas mean serum calcium levels did not change
significantly from baseline values in the sevelamer group.
Thus, the significant difference in calcium-phosphate
product can only be explained by better control of serum
phosphorus in the calcium acetate group. In this regard,
because the magnitude of the change in serum phospho-
rus (Cavg = 1.08 mg/dL over the 8-week study) is larger
than the average change in serum calcium, the attained
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serum phosphorus seems to be the most important vari-
able in determining the observed difference in calcium-
phosphorus product between the treatment groups.
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Using the right MDRD
equation
To the Editor: Estimating the prevalence of renal in-
sufficiency in any patient population is of course a crucial
issue. The earlier renal insufficiency is diagnosed, the best
care is to be provided to the patient, especially in terms
of slackening the progression of renal failure and adjust-
ing drugs dosage when required. In their article, Garg
et al [1] mentioned that they estimated the renal func-
tion of their patients using the Cockcroft-Gault and the
Modification of Diet in Renal Disease Study (MDRD)
formulas. They thus cited Cockcroft and Gault [2] and
Levey et al [3] works in references. The authors fur-
ther detailed the formulas they used in the Appendix of
their article. It is important to remember that Levey et
al tested in their work seven different formulas for es-
timating glomerular filtration rate. They concluded that
among those equations, only one (equation 7) gave sat-
isfactory results. This seventh equation is the one that
should be used in other works when renal function is to
be estimated with the MDRD equation. Unfortunately,
the formula called MDRD formula in Garg’s article is
not the formula validated by Levey et al in the MDRD
article.
MDRD equation for estimating glomerular filtration
rate (GFR):
GFR(mL/min/1.73m2) = 170 × [PCR]−0.999
× [Age]−0.176 × [SUN]−0.170
× [Alb]+0.318
× 0.762 if patient is female
× 1.180 if patient is black
with PCR = serum creatinine concentration (mg/dL), Age
= age of the patient (years), SUN = serum urea nitrogen
(mg/dL), and Alb = serum albumin concentration (g/dL).
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We thank Launay-Vacher et al for their comment. Esti-
mating glomerular filtration rate (GFR) in nursing home
elderly is critical for drug dosing and end of life care,
which may include dialysis. As we highlight in our pa-
per, there are limitations to the use of both Cockcroft-
Gault and Modification of Diet in Renal Disease Study
(MDRD) formulas. The best methods of estimating GFR
for patient care in this population remain to be clarified.
The abbreviated MDRD formula was used in our re-
search study [1]. For transparency of reporting we in-
cluded the formula in the Appendix. The abbreviated
MDRD equation is used throughout Kidney Disease
Outcomes Quality Initiative (K/DOQI) clinical practice
guidelines [2], facilitating comparisons with our results.
Levey et al suggest both MDRD equation 7 and the
abbreviated MDRD formula correlate well with 125I-
iothalamate GFR in middle-aged adults with kidney dis-
ease (R2 = 0.90 and 0.89, respectively) [1]. Finally, the
predictive validity of the abbreviated MDRD formula
has been established—low GFR was a stronsg predictor
of death and end-stage renal disease in a sample of 27,998
adults followed for 5 years [3]. Thus, we strongly dis-
agree with Launay-Vacher et al’s assertion that MDRD
equation 7 was the only valid formula to be used in our
analyses.
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